Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
| Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
|---|---|---|---|---|
| Frahm J et al. | 2010 | intact cell/cell culture, murine bone marrow-derived macrophages | magnetic field, low frequency, 50/60 Hz | 1 mT |
| Kim J et al. | 2012 | intact cell/cell culture, HeLa cell line (human adenocarcinoma cell line) and IMR90 (human lung fibroblasts) | magnetic field, low frequency, 50/60 Hz | 2–14 mT |
| Cho SI et al. | 2012 | animal, rat/Sprague-Dawley, whole body | magnetic field, low frequency, 50/60 Hz | 1.8–2 mT |
| Martinez MA et al. | 2012 | intact cell/cell culture, NB69 cells (human neuroblastoma cells) | magnetic field, low frequency, 50/60 Hz | 100 µT |
| Iorio R et al. | 2013 | intact cell/cell culture, C2C12 cells (undifferentiated mouse myoblasts) | magnetic field, low frequency, 50/60 Hz | 1 mT |
| Cheng G et al. | 2011 | intact cell/cell culture, primary rat osteoblast cells | magnetic field, low frequency, 50/60 Hz, co-exposure | 1.8 mT |
| Patruno A et al. | 2012 | intact cell/cell culture, THP-1 cells (human monocytic leukemia cell line) | magnetic field, low frequency, 50/60 Hz, co-exposure | 1 mT |
| Yamaguchi DT et al. | 2002 | intact cell/cell culture, ROS 17/2.8 (osteoblast-like cells) and MC3T3-E1 cells (mouse osteoblast-like cells) | magnetic field, low frequency, 50/60 Hz, therapeutic/medical device | 0.6–1.25 mT |
| Golbach LA et al. | 2015 | intact cell/cell culture, HL-60 and PLB-985 cells (human acute myeloid leukaemia cell lines) | magnetic field, low frequency, intermediate frequency, 50/60 Hz, co-exposure | 5 µT–2.5 mT |
| Aldinucci C et al. | 2000 | intact cell/cell culture, U-373 MG (human astrocytoma cell line) | magnetic field, signals/pulses, 50/60 Hz | 3 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.
